NGEN Latest Press Releases

-- April 7, 2026 --

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia Globe Newswire 7:30 AM

-- March 31, 2026 --

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates Globe Newswire 7:45 AM

-- March 12, 2026 --

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange Globe Newswire 4:15 PM

-- March 4, 2026 --

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs Globe Newswire 7:30 AM

-- February 18, 2026 --

NervGen Pharma to Participate at Upcoming Investor Conferences Globe Newswire 7:30 AM

-- February 12, 2026 --

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams Globe Newswire 4:15 PM

-- February 11, 2026 --

NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium Globe Newswire 7:00 AM

-- February 9, 2026 --

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury Globe Newswire 7:00 AM

-- January 20, 2026 --

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing Globe Newswire 7:00 AM

-- January 8, 2026 --

NervGen Pharma Begins Trading on Nasdaq Today Globe Newswire 6:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software